VERICI DX PLC LS-001
Research VERICI DX PLC LS-001 (63V) on Bullrun: market cap EUR 3.43M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker63V
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyEUR
- Market capEUR 3.43M
- Financial periodFY2025
- RevenueUSD 3.66M
- Revenue growth9.7%
- Net income-USD 6.93M
- Free cash flow-USD 8.45M
- Gross margin77.5%
Valuation Snapshot
latest market cap is EUR 3.43M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.66M | -USD 6.93M | -USD 8.45M | 77.5% | -0.01 | USD 3.34M | USD 197.00K | USD 6.51M |
| FY2024 | USD 3.34M | -USD 5.87M | -USD 6.21M | n/a | -0.03 | USD 4.06M | USD 371.00K | USD 5.27M |
| FY2023 | USD 1.01M | -USD 8.73M | -USD 7.39M | n/a | -0.05 | USD 2.65M | USD 540.00K | USD 3.56M |
| FY2022 | USD 0 | -USD 11.41M | -USD 11.38M | n/a | -0.07 | USD 9.81M | USD 700.00K | USD 11.51M |
| FY2021 | USD 0 | -USD 8.33M | -USD 7.30M | n/a | -0.06 | USD 10.34M | USD 0 | USD 11.99M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 3.43M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About VERICI DX PLC LS-001
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; Clarava, a pre-transplant prognosis test for the risk of early acute rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is VERICI DX PLC LS-001's market cap?
VERICI DX PLC LS-001's market capitalization is EUR 3.43M.
What does VERICI DX PLC LS-001 do?
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; Clarava, a pre-transplant prognosis test for the risk of early acute rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure.